Go to main content

to isofolmedical.com

SV EN

Scientist_pipette_gloves_facing right

Press releases

All press releases from Isofol, including regulatory news and company updates, for investors, media and the market.

Published: 31 March 2026 Regulatorisk

Isofol receives gross proceeds of 18.9 MSEK in connection with the exercise of warrants and guarantee commitments for warrants of series TO1, and resolves on a directed share issue

Published: 18 March 2026 Regulatorisk

Isofol secures license rights for arfolitixorin in autism

Published: 13 March 2026 Regulatorisk

The subscription price for warrants of series TO1 in Isofol has been set at SEK 0.48 and the exercise period commences on 16 March 2026

Published: 11 March 2026 Regulatorisk

Isofol receives top guarantee commitment and letters of intent corresponding to 42 percent of upcoming warrant exercise

Published: 9 March 2026 Regulatorisk

Isofol’s Nomination Committee proposes election of Christian Haglund as new Board Director

Published: 3 March 2026 Icke-regulatorisk

Isofol presents at investor meetings in March

Published: 24 February 2026 Regulatorisk

Isofol provides update on the ongoing phase Ib/II clinical study of arfolitixorin

Published: 18 February 2026 Regulatorisk

Isofol Medical AB (publ) publishes year-end report, January – December 2025

Published: 9 January 2026 Icke-regulatorisk

Isofol participates in the ASCO GI congress

Published: 1 December 2025 Icke-regulatorisk

Isofol participates in several investor meetings in December and January

Published: 13 November 2025 Icke-regulatorisk

European Patent Office intends to grant a new patent for Isofol’s arfolitixorin

Published: 12 November 2025 Regulatorisk

Isofol Medical AB (publ) publishes interim report, January–September 2025

Cookies

This website uses cookiesfor statistics and user experience.